Abstract
Gastric cancer is one of the most common cancers and the third cause of cancer-related death worldwide. The treatment of GC patients improved due to advancements in surgery, radiotherapy and chemotherapy. However, the long-term survival rate of patients with gastric cancer remains around 20%. Thus, development of novel therapeutic approaches is of great interest, in order to reduce the need for mutilating surgeries and morbid adjuvant therapies. For many years, it was believed that the RNA was a mere intermediate molecule in the genetic information flow. However, during the past decades, with the advent of new sequencing technologies, it was revealed that non-coding RNAs play important roles in many different biological processes. The Wnt/β-catenin signaling pathway has been reported to regulate crucial events during neoplasic development, such as cell differentiation, proliferation, invasion, migration, apoptosis, and angiogenesis. In this review, we will focus on microRNAs and long non-coding RNAs that have been implicated in gastric cancer tumorigenesis via modulation of the Wnt/β-catenin signaling pathway, which provided some biomarkers to prognosis, diagnosis, and therapy.
Highlights
Depending of the size of the molecule, ncRNAs may be divided into long non-coding RNAs, if the transcript contains more than 200 nucleotides; or small ncRNAs, when they are shorter than 200 nucleotides [17]
Differently from miRNAs, which act in the cytoplasm of the cells, where they either degrade mRNA or repress its expression, long non-coding RNAs (lncRNAs) were shown to have a wide variety of functions (Figure 2)
The results indicated that TRIM29 acted as an oncogene in Gastric CancerGastric cancer (GC), improving cell cycle progression and decreasing apoptosis
Summary
Gastric cancer (GC) is the fifth most common cancer and the third cause of death caused by cancer worldwide, with over 1,000,000 new cases per year and more than. The intestinal type is more incident, with males being more affected than females (roughly twofold) These patients usually have a well-differentiated tumor and, a better prognosis. The diffused type is less frequent; its incidence rate has been increasing by 3.6% per year, on average. This type is characterized as less differentiated, and the patients have a worse prognosis [9,10]. GC is diagnosed late due to the fact the patients are usually asymptomatic or present nonspecific symptoms for a long period of time These tumors often metastasize by the time of diagnosis, which contributes to the poor prognosis of the disease. Various researchers have been working on identifying molecular targets for diagnosis and prognosis of GC, as well as for developing novel therapeutic approaches to reduce the need for mutilating surgeries and morbid adjuvant therapies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
